Drug Trial Radar · NCT01212991
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Mar 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,717
Actual
Start
Sep 16, 2010
Primary completion
Sep 30, 2013
Study completion Feb 14, 2019
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
- First posted
- Oct 1, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the benefit of enzalutamide versus placebo as assessed by overall survival and progression-free survival in patients with progressive metastatic prostate cancer who have failed androgen deprivation therapy but not yet received chemotherapy.
Conditions
- Prostate Cancer
Interventions
EnzalutamideDrug
Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
PlaceboDrug
Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: During study period (up to 3 years)
- Radiographic Progression-free Survival (rPFS)Time frame: During study period (up to 20 months)
Locations
269 sites in 22 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
The University of Arizona Cancer Center-North Campus
Tucson, Arizona
The University of Arizona Cancer Certer-North Campus
Tucson, Arizona
Cancer Center Oncology Medical Group
La Mesa, California
Keck Hospital of USC
Los Angeles, California
LAC&USC Medical Center
Los Angeles, California
USC/Norris Comprehensive Cancer Center / Investigational Drug Services
Los Angeles, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California
Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services
Los Angeles, California
UCLA Clark Urology Clinic
Los Angeles, California
North County Oncology Medical Clinic, Inc
Oceanside, California
UC Davis Medical Center
Sacramento, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Medical Oncology Associates-SD
San Diego, California
Sharp Memorial Hospital Investigational Pharmacy
San Diego, California
Sharp Rees-Stealy
San Diego, California
Stanford University Medical Center
Stanford, California
Anschutz Cancer Center Pavilion Pharmacy
Aurora, Colorado
University of Colorado Hospital, Anschutz Cancer Pavilion
Aurora, Colorado
Lynn Cancer Institute Center for Hematology Oncology
Boca Raton, Florida
Northwestern Medical Faculty Foundation
Chicago, Illinois
Northwestern Memorial Hospital
Chicago, Illinois
Jewish Hospital & St. Mary's Healthcare, Inc.
Louisville, Kentucky
Brigham & Women's Hospital
Boston, Massachusetts
Beth Israel Deaoness Medical Center
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Karmanos Cancer Institute Weisberg Cancer Treatment Center
Farmington Hills, Michigan
Mayo Clinic
Rochester, Minnesota
Barnes-Jewish St. Peters Hospital
City of Saint Peters, Missouri
Barnes-Jewish West County Hospital
Creve Coeur, Missouri
BJH Pharmacy
St Louis, Missouri
Barnes-Jewish Hospital
St Louis, Missouri
Washington University School of Medicine
St Louis, Missouri
Nebraska Methodist Hospital
Omaha, Nebraska
The Mount Sinai Medical Center
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Cancer Centers of North Carolina
Cary, North Carolina
Levine Cancer Institute
Charlotte, North Carolina
Showing 40 of 269 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.